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Introduction
This report summarises the main trends in communicable disease in Northern Ireland
during 2003. It is primarily based on laboratory reports forward to CDSC (NI) and
information supplied by Consultants in Communicable Disease Control. This is a more
detailed annual summary than in previous years and replaces our annual report. The data
for 2003 should be regarded as provisional to allow for late reporting of results and further
typing of organisms. CDSC (NI) is extremely grateful to colleagues in Trusts and Boards for
providing timely data and information on a wide range of infections and communicable
disease issues.
This summary can also be downloaded from our website http://www.cdscni.org.uk
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Gastrointestinal infections
Notifications of food poisoning increased steadily from1991 to 2000. Between 2000 and
2002 there was a decrease of 47% (from 2285 cases notified in 2000 to 1220 in 2002).
There has been a slight increase to 1268 cases (4%) during 2003. Laboratory confirmed
reports of Campylobacter and Salmonella have also declined between 2002 and 2003,
although reports of Cryptosporidium have slightly increased.
Figure 1: Food poisoning: Notifications and laboratory reports, 1990-2003,
Northern Ireland
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Campylobacter
Reports of Campylobacter infection first exceeded reports of Salmonella infection in Northern Ireland in
1991, and Campylobacter remains the single most common form of bacterial food poisoning with 740
reports in 2003 (approximately 3.5 times more than Salmonella).  Reports increased steadily from 1993,
peaking at 1001 in 2000.  Since then there has been a 26% reduction in reports. This is in line with
trends in Great Britain: between 2000 and 2003 reports of Campylobacter have decreased by 24%,
36% and 31% in England, Wales and Scotland respectively.
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Figure 2: Laboratory reports of Campylobacter, 1990-2003, Northern Ireland
Salmonella
Source: CDSC (NI)
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Figure 3: Laboratory reports of Salmonella, 1990-2003, Northern Ireland
Salmonella (total)
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Having increased during the 1990s such that in 1999, the incidence of Salmonella in Northern Ireland
exceeded that in the rest of the UK for the first time, Salmonella infection has shown a marked
reduction for a fourth successive year.  In 2000 424 laboratory reports were received, 364 in 2001, 239
in 2002 and 210 in 2003.  This represents a reduction of approximately 70% since the peak in 1999.
5
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1999 2000* 2001* 2002* 2003*
Total Salmonella 689 Total Salmonella 425 Total Salmonella 367 Total Salmonella 240 Total Salmonella 213
enteritidis 462 enteritidis 235 enteritidis 179 enteritidis 98 enteritidis 94
typhimurium 124 typhimurium 93 typhimurium 76 typhimurium 71 typhimurium 43
virchow 12 dublin 7 virchow 9 virchow 5 infantis 4
bredeney 10 hadar 7 hadar 5 montevideo 4 kottbus 4
hadar 6 virchow 6 dublin 4 braenderup 3 virchow 4
braenderup 5 bredeney 5 braenderup 3 hadar 3 bredeney 3
heidelberg 5 kentucky 4 anatum 2 infantis 3 dublin 2
agona 4 derby 3 montevideo 2 agona 2 newport 2
java 4 infantis 3 stanley 2 newport 2 ohio 2
stanley 4 java 3 weltevreden 2 panama 2
thompson 4 muenster 3 senftenberg 2
anatum 2 agona 2
hidalgo 2 blockley 2
infantis 2 brandenburg 2
javiana 2 heidelberg 2
mbandaka 2 lagos 2
tenessee 2 livingstone 2
Table 1 lists serotypes for which more than one report was received from 1999 to 2003.  S. enteritidis
and S. typhimurium are consistently the top two serotypes.
Table 1: Frequently reported serotypes of Salmonella, 1999-2003, Northern Ireland
* Total includes 1 report of S. paratyphi in 2002, and 1 report of S. typhi in 2000, 3 in 2001 and 3 in 2003
Source: CDSC (NI)
Salmonella enteriditis is the most frequently isolated serotype, accounting for almost 40% of the total
for 2002 and 44% of the total in 2003. The reduction in salmonellosis in the past four years can be
attributed to the reduction in S. enteritidis. Since the peak in 1999 when 462 reports were received,
reports of S. enteritidis have shown a reduction of 80%. The most frequently isolated phage type (PT)
of S. enteritidis is PT 4; 397 reports were received in 1999, accounting for 86% of S. enteritidis
isolations and 58% of all reported salmonella infections in Northern Ireland during that year.  In 2003,
by contrast, there were 18 reports of S. enteritidis PT 4 received, accounting for 19% of S. enteritidis
isolations and 9% of all reported salmonella infections in Northern Ireland.
Table 2: Salmonella enteritidis phage types reported in
2003, Northern Ireland
Phage type Number of reports received
PT 1 20
PT 1C 1
PT 4 18
PT 5A 2
PT 6 14
PT 6A 3
PT 8 5
PT 12 3
PT 14B 2
PT 21 7
PT 24 3
PT 48 1
PT 53 1
Untyped 14
Total 94
Source: CDSC (NI)
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Reports of Salmonella typhimurium exceeded reports of Salmonella enteritidis only once during the
past decade, in 1997, and then began to decline.  It is the most commonly isolated serotype after S.
enteritidis.  The most frequently isolated phage type of S. typhimurium during the past decade is
definitive type (DT) 104: 23% of S. typhimurium isolates in 2003 were DT 104.  This compares to 53%
in 1999.  Laboratory reports of S. typhimurium fell by 65% from 124 in 1999 to 43 in 2003 and reports
of S. typhimurium DT 104 fell by 85% from 66 in 1999 to 10 in 2003.
There have been no Salmonella outbreaks reported to CDSC (NI) since 2001. The continuing decrease in
Salmonella incidence in Northern Ireland is in contrast to England where the number of reports of
individual cases and outbreaks have risen.  Between September 2002 and November 2003, 59
Salmonella enteritidis outbreaks occurred in England and Wales affecting over 2,262 people. Foods
made from eggs, particularly eggs imported from Spain, were identified as the cause of many of these
outbreaks. Over half (58%) of the outbreaks were linked to the consumption of foods prepared with
raw shell eggs.
E. coli O 157
On average there have been 47 laboratory reports of E. coli O 157 reported annually between 1999-
2003.  Fifty three reports were received in 2003, of which 51 were vero-toxigenic. This compares to 27
reported during 2002, all of which were vero-toxigenic.
Figure 4: Laboratory reports of E. coli O 157, 1990-2003, Northern Ireland
E. coli O 157 (VTEC)
Total E. coli O 157
Source: CDSC (NI)
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Transmission occurs via contaminated foodstuffs - beef and beef products, milk, and vegetables have
been associated with cases or outbreaks – or contact with infected animals, particularly on farms or in
animal sanctuaries. Person-to-person spread can occur by direct contact (faecal oral), particularly in
households, nurseries, and infant schools. One outbreak was reported to CDSC (NI) in 2003, which
occurred in a nursery in the Northern Health and Social Services Board.  Sixteen of the 53 reports
received in 2003 were associated with this outbreak.
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Source: CDSC (NI)
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Cryptosporidium
Figure 5: Laboratory reports of Cryptosporidium, 1990-2003, Northern Ireland
There were 140 laboratory reports of Cryptosporidium received in 2003, compared with 126 in 2002 –
an increase of 11%.  Exceptionally high numbers of reports were received in 2000 and 2001 due to 3
large waterborne outbreaks accounting for 437 reports in total.  Thirty-three of the reports received
during 2003 were associated with travel to Majorca, where an outbreak linked with a swimming pool
occurred during July.
Foodborne and gastrointestinal outbreaks: 2003
Outbreak surveillance is primarily based on reports received from Consultants in Communicable Disease
Control. During 2003 CDSC (NI) was made aware of three foodborne outbreaks affecting at least 53
people and 44 other gastro-intestinal outbreaks affecting at least 559 people. This compares with two
foodborne outbreaks and 68 gastrointestinal outbreaks in 2002.
There have been no Salmonella outbreaks reported during 2003 or 2002, contributing to the marked
decrease in cases of Salmonella reported since 2000.
Viral or suspect viral infections were thought to be the cause of 38 non-foodborne outbreaks of
gastroenteritis and in three instances, the outbreak was due to an unknown organism. These infections
can spread rapidly in facilities such as hospitals and residential/nursing care facilities. There were 22
hospital outbreaks, 18 in residential/nursing homes and one in a childcare facility reported in 2003. The
other three outbreaks occurred outside Northern Ireland but involved local residents or local
laboratories. An outbreak of Cryptosporidium was reported involving a hotel swimming pool in Majorca.
E. Coli O 157 was the causative agent in an outbreak in Dublin and an outbreak of SRSV occurred on a
cruise ship which had docked in Belfast. Twenty-six of the confirmed viral outbreaks were secondary to
Small Round Structured Viruses (SRSV) (Noroviruses) and were thought to be caused by person-to-
person spread.
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Table 3: General outbreaks of foodborne and other gastrointestinal illness reported to CDSC (NI), 2003
                                              Foodborne outbreaks
Month Board Location Organism Suspect vehicle2 No. ill3 No +ve
Jan N Residential Home Viral Foodborne followed by person/person 12 residents, 5 staff 0
Dec W Residential Home Viral Foodborne followed by person/person 8 n/a
Dec E/N Sandwich Retailer ?Viral 28 n/a
                                                                  Other gastro-intestinal outbreaks
Month Board Location Organism Suspect vehicle2 No. ill3 No +ve
Jan N Nursing Home SRSV 13 residents, 4 staff 1
Jan N Hospital SRSV 1
Jan N Hospital SRSV 2
Jan N Hospital SRSV Person-to-person 26 2
Jan N Nursing Home Viral Person-to-person 10 residents, 5 staff 0
Jan N Nursing Home Viral Person-to-person 20 residents, 10 staff 0
Jan E Hospital SRSV 3
Jan N Hospital SRSV Person-to-person 78 5
Jan N Hospital ?Viral Person-to-person 7 0
Jan E Hospital SRSV 2
Jan E Hospital SRSV 2
Feb E Hospital SRSV 2
Feb E Hospital SRSV 3
Feb E Hospital SRSV 1
Feb E Hospital SRSV 5
Feb E Hospital SRSV 1
Feb E Hospital SRSV 1
Feb E Hospital SRSV 2
Feb N Nursing Home SRSV Person-to-person 10 residents, 5 staff 2
Feb N Hospital SRSV 8
Feb N Residential Home SRSV Person-to-person 16 residents, 2 staff 0
Feb S Nursing Home Unknown Person-to-person 22 residents, 27 staff 0
Mar N Hospital SRSV 5
Mar N Nursing Home Viral Person-to-person 17 residents, 5 staff 0
Mar E Hospital SRSV 3
Mar S Nursing Home SRSV Person-to-person 44 0
Mar N Hospital SRSV Person-to-person 5 2
Mar N Nursing Home Viral Person-to-person 19 residents, 9 staff 0
Apr N Hospital SRSV 1
Apr N Nursing Home Viral Person-to-person 10 residents, 4 staff 0
May W Nursing Home SRSV 1
May N Nursing Home Viral Person-to-person 10 residents, 3 staff 0
May N Nursing Home Viral Person-to-person 26 residents, 15 staff 0
May S Nursing Home Unknown Person-to-person 4 0
May N Nursing Home Viral Person-to-person 14 residents, 5 staff 0
Jun S Nursing Home Unknown Person-to-person 23 0
July ~ Hotel Cryptosporidium Person-to-person
Aug ~ Café E. Coli O 157 2
Aug E Cruise Ship SRSV 7
Sept N Nursery E. Coli O 157 Person-to-person 16
Sept N Residential Home Viral Person-to-person 18 residents, 4 staff 0
Oct W Hospital Viral 10 staff, 13 patients
Dec S Hospital SRSV Person-to-person 11 patients, 13 staff 1
Dec S Nursing Home Viral Person-to-person 5 patients, 1 staff 0
1General outbreaks involve members of more than one household;
2Local investigations may not provide conclusive evidence of vehicles of infection. Vehicles are therefore designated ‘suspect’;
3The number known to be ill.
Source: CDSC (NI)
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Imported Gastrointestinal Infections
Salmonella
There were 213 laboratory reports of individuals with Salmonella infection reported to
CDSC (NI) in 2003. In contrast to the data collected for isolates for the same period in 2002
where 80 (33%) were believed to have been acquired abroad (i.e. outside the UK), 101
isolates (47%) in 2003 had a history of foreign travel.
Over half were thought to have acquired their infection in Spain (including Canary Islands and Balearic
islands) - these three areas are the most popular holiday destinations for British holidaymakers1. The
remainder acquired infection in Greece (including Greek Islands), Portugal and Turkey.  Other countries
included were:  Australia, Cuba, Czech Republic, Dominican Republic, Egypt, France, Italy, Philippines,
Palestine, Republic of Ireland, Thailand, Tunisia, UAE and USA. There were an equal number of males and
females and ages ranged from 1 – 71 years. Table 4 shows the serotypes reported to CDSC (NI) in 2003.
Table 4:  Laboratory Reports of Salmonella, 2003, Northern Ireland
Serotype Number of Number thought to have been acquired
reports received abroad and country
S. blockley 1 Cyprus (1)
S. braenderup 1  
S. bredeney 3  
S. derby 1 Phillipines (1)
S. dublin 2 RoI (1)
S. eastbourne 1 Palestine (1)
S. enteritidis (PT4) 94 (18) Czech Republic (1), France (1), Greece (7), Portugal (5), RoI (1),
Spain (31), Tunisia (1), Turkey (1), Unknown (1)
S. give 1 RoI (1)
S. hadar 1  
S. heidelberg 1
S. infantis 4 Spain (3)
S. Johannesburg 1 UAE (1)
S. kottbus 4
S. mikawasima 1  
S. montevideo 1  
S. newport 2 Egypt (1)
S. ohio 2
S. spp 39 Australia (2), Cuba (1), Dominican Republic (1), Greece (1),
Italy (1), Portugal (4), Spain (9), Thailand (2), Turkey (2), USA (1)
S. souza 1
S. tambacounda 1  
S. typhi 3 Bangladesh (1)
S. typhimurium (DT 104) 43 (10) Spain (9), Turkey (2), UAE (2)
S. virchow 4 Spain (3)
S. wenham 1 Tunisia (1)
Total 213 101
2
Source: CDSC (NI)
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Figure 6: Travel Related Salmonella Reports Among NI Residents, 2003
Other Countries*
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N = 101 (47%) *ROI = 3 Source: CDSC (NI)
Other Gastrointestinal Infections
Other gastrointestinal infections with a history of having travelled abroad during 2003 were as follows:
Table 5:  Other Gastrointestinal Infections Acquired Abroad, 2003, Northern Ireland
Organism Number of reports with Countries
history of foreign travel
Campylobacter 47 Australia (1), Barbados (1), Egypt (1), Greece (3),
India (1), Kenya (1), Portugal (1), RoI (13), Spain (20),
Thailand (2), Tunisia (1), Turkey (1), Med Cruise (1)
Cryptosporidium 47 Canada (1), France (3), Greece (1), India (1),
RoI (3), Spain (36), Unknown (2),
Giardia lamblia 7 India (2), RoI (1), Spain (2), Thailand (2)
Shigella flexneri 2 Sri Lanka (1), Tanzania (1)
Shigella sonnei 6 Africa (1), India (3), Mexico (1), Spain (1),
E. Coli O 157 4 RoI (1), Spain (2), Unknown (1)
Adenovirus 1 Spain (1)
C. difficile Toxin 3 Spain (3)
Rotavirus 1 Spain (1)
SRSV 1 Spain (1)
Source: CDSC (NI)
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Table 6 shows the total number of laboratory reports of gastrointestinal infections received by CDSC (NI)
in 2003, and the number and proportion of total reports associated with foreign travel.
Table 6:  Total Gastrointestinal Infections Acquired Abroad, 2003, Northern Ireland
Figure 7:  Gastrointestinal Infections Acquired Abroad, 2003, Northern Ireland
Salmonella
101 (46%)
Shigella
8 (4%)
Campylobacter
47 (21%)
Giardia
7 (3%)
Cryptosporidium
47 (21%)
N = 220
Others
10 (5%)
Source: CDSC (NI)
Organism Total reported in 2003 Acquired abroad
(% of total reports of each organism)
Salmonella 213 101 (47%)
Campylobacter 740 47 (6%)
Cryptosporidium 140 47 (34%)
Giardia lamblia 18 7 (39%)
Shigella 13 8 (62%)
E. coli O 157 53 4 (8%)
Adenovirus 145 1 (0.7%)
C. difficile Toxin 1014 3 (0.3%)
Rotavirus 554 1 (0.2%)
SRSV 115 1 (0.9%)
Salmonella was the most common laboratory confirmed gastrointestinal infection among Northern
Ireland residents acquired outside the UK. The large number of Cryptosporidium isolates was due to an
outbreak associated with a hotel swimming pool in Majorca.
References:
1 ABTA.  ABTA’s Holiday Trends 2003. 2003.
Available at http://www.abtamembers.org/press/kit/trends.htm
Source: CDSC (NI)
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Human Brucellosis in Northern Ireland, 2003
Brucellosis is a zoonotic disease which is mainly transmitted from cattle, sheep, goats or
pigs to humans. In livestock, chronic lifelong infection, where the organisms localise in the
reproductive organs, gives rise to abortions, the birth of weak offspring, and reduction in
milk production. Organisms are shed in large numbers in milk, urine and cyetic products.
Control and eradication of the disease in livestock is achieved through identification and
elimination of infected herds.
It is transmitted to humans through inhalation, contact with infected post-partum materials, and
ingestion of unpasteurised milk or dairy products. The human form of the disease presents as a flu-like
illness with myalgia, fatigue, night sweats and intermittent fever which can occur for lengthy and
variable periods of time. Severe chronic complications can occur in some individuals if they are
inadequately treated. Treatment in humans is normally with a tetracycline, like doxycycline, along with
gentamicin or rifampacin for a period of at least 6 weeks.
The disease does not occur in the United Kingdom in goats, sheep or pigs. It was practically eradicated
from cattle in 1984, and, until recently, the last outbreak of bovine brucellosis occurred in Great Britain
in 19931,2.  Whereas the small numbers of cases of human brucellosis in the UK are all acquired abroad,
most Northern Ireland cases are indigenous.
In Northern Ireland, human infection is mainly acquired through contact with infected cattle. Prior to
1997, bovine brucellosis was detected only at low levels; however, it has been on the increase across the
Province since then. The number of Brucella-infected herds rose from 3 in 1995/1996 to 172 in 1999/
2000.  In particular, there has been a high incidence of reactor herds in the south and west of the
Province. As a consequence, particularly in these areas, levels of the disease in humans have also
increased, with a large number of cases being recorded as occupationally acquired.
Although human brucellosis is not notifiable, it is a reportable disease under the Reporting of Injuries,
Diseases and Dangerous Occurrences Regulations (Northern Ireland) 1997 (RIDDOR) to the Health and
Safety Executive. A multi-agency Brucellosis Advisory Group has been established to: share information
on human and animal brucellosis, identify high risk work activities, promote best practice in disease
prevention, control and management and raise awareness in ‘at risk’ groups through targeted
information campaigns. Professionals have also been targeted in the awareness campaign.
3
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NI Incidence
% Positive Herds*
Source: CDSC (Northern Ireland): DARDNI
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Figure 8: Human Brucellosis in Northern Ireland 1990-2003
Between 1 January 1998 and 31 December 2003, 86 cases of human brucellosis were reported to
CDSC (NI). Annual totals peaked in 2002, with 28 cases being reported. The total in 2003 has fallen by
50% to 14 cases.  Of the 86 cases, 57 (67%) were known to be farmers, 36 (63%) of which were known
to have been exposed to Brucella-positive herds. Six cases had been associated with an abattoir which
was contracted to cull Brucella-positive herds. Two cases were veterinarians who both had histories of
working with Brucella-positive herds. Only one case, a baker, had no obvious exposure to any risk
factors.  One case in 2003 was a child who lived on a farm. The occupation in 18 cases was unknown.
Bovine herd incidence increased 5-fold between 1996 (0.02%) and 1997 (0.11%), and continued to
increase to a level of 1.37 in 2002. The rate has dropped to 0.79 % in 2003. The geographical
correlation between positive herds and human cases continues to be noted.
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Enhanced Surveillance of Influenza in
Northern Ireland (ESINI)
Influenza is an acute viral disease of the respiratory tract caused by infection with the
influenza virus, of which there are three main types; influenza A, B and C. The incubation
period for influenza is 1-3 days and disease onset is rapid thereafter. Symptoms include
fever, myalgia, headache, coryza, sore throat and cough. Such symptoms are common to a
range of viral upper respiratory tract infections, therefore patients may be described as
having ‘flu or ‘flu-like illness (FLI).
Enhanced Surveillance of Influenza in Northern Ireland (ESINI) was introduced as a pilot study in October
2000 and has continued each season thereafter. The principal aim of the project is to provide an early
warning scheme for influenza circulation in NI. The scheme involves the weekly compilation of
consultation data from sentinel GP practices and call-rate data from out-of-hours Co-Operatives (Co-
Ops). A subset of sentinel GPs each year also carry out virological surveillance. This entails nasal and
throat swabbing of patients presenting with clinical influenza. Swabs are sent to the Regional Virus
Laboratory where they are tested for the presence of influenza, together with a number of other
respiratory pathogens.
During each ‘flu season, a NI report is published weekly and distributed to Health Boards, Trusts,
Consultants in Communicable Disease Control, data providers and other interested parties. Weekly data
is also sent to Colindale for inclusion in the UK dataset.
In April 2002, Northern Ireland became an associate member of the European Influenza Surveillance
Scheme (EISS) and, in September 2003, the Province was accorded full membership of EISS.  ESINI data
is exported weekly to EISS for inclusion in the European surveillance programme.
2002/03 Season
In Northern Ireland, enhanced surveillance of influenza for 2002/03 commenced in week 40 of 2002. A
total of 24 sentinel GP practices, situated throughout the Province, took part in surveillance. Fifteen of
these 24 practices also agreed to be involved in enhanced virological monitoring, by swabbing selected
patients who presented with clinical influenza.
Five out-of-hours medical co-operatives (Co-Ops) also agreed to supply call data, broken down by age
and sex, for enhanced surveillance purposes.
Throughout the 2002/03 season, consultation rates for influenza remained at very low levels, in
accordance with that observed throughout the UK and Ireland.  As in previous years, consultation rates
for FLI remained much higher and more variable than those for influenza.
4
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The main peak in clinical activity for the 2002/03 season occurred between Week 04 and Week 09,
when children aged 0-14 were the group most affected by illness. This peak also corresponded to the
first laboratory confirmed influenza infections of the season; influenza B in hospitalised children.
The full 2002/03 season summary may be downloaded from http://www.cdscni.org.uk.
2003/04 Season
Twenty-three sentinel GP practices and 5 Co-Ops are participating in enhanced surveillance of influenza
this season and, as in 2002/03, 15 of the sentinel practices were also involved in virological monitoring.
Based on historical data, influenza activity in the current season commenced some three months earlier
than would, normally, be expected. Between Week 40 and Week 45, GP consultation rates rose sharply
and, in Week 45, the combined GP consultation rate for influenza and FLI was higher than that
recorded for any week since the ESINI scheme commenced (Figure 9).
Children, particularly those aged 0-4 years, have been the group most affected this winter. There has
been very little influenza in circulation over the past few years and the opportunity for development of
immunity has been restricted. Illness in young children is, therefore, not unexpected. The first
laboratory confirmed case of influenza A H3 in the 0-4 age-group occurred in mid-October 2003 and,
by the end of January 2004, a further 52 cases had been confirmed.
Individual weekly bulletins are available to download, as they are published, from the CDSC (NI) website.
FLI rate 2003-04
FLU rate 2003-04
FLI rate 2002-03
FLI rate 2001-02
FLI rate 2000-01
Source: CDSC (NI) Enhanced Surveillance of Influenza
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Figure 9: GP Consultation Rates for Influenza and ‘Flu-Like Illness
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Influenza Vaccination in Northern Ireland
2002/03
During the winter of 2002-2003, DHSSPS set an uptake target of 70 % for influenza vaccination in
those aged 65 and over. In addition to the immunisation of those aged over 65 years, a target of 60%
influenza immunisation uptake among the under 65 “at risk” population was also set. Prior to the
commencement of the 2002/03 campaign it was agreed that, across Northern Ireland, a nominal 10%
of the under 65 population should be considered “at risk”.
All four Health and Social Services Boards met or exceeded the target set for those aged 65 and over
and the overall uptake in NI, for this age group, was 72% (range 71% - 74%). The overall uptake in the
under 65 “at risk” population for 2002/03 was 56% (range 52% - 62%), which may reflect variation
between Boards and between individual GP practices in the proportion of under 65s considered to be
“at risk”. An analysis of the 2002-2003 vaccination campaign may be found in the Monthly Report for
April 2003 (Volume 12 No.2), available at http://www.cdscni.org.uk
2003/04
For winter 2003/04, DHSSPS again set uptake targets of 70% for influenza vaccination in those aged 65
and over and 60% influenza immunisation uptake among the under 65 “at risk” population.
By 30 November 2003, the uptake target in those aged 65 and over had already been met and
exceeded, with an overall NI uptake rate of 70.4% (range 69.1% to 73.7%). This is despite a 0.4%
increase in the number of those aged 65 and over between 2002 and 2003.
By the same date, the uptake target in “at risk” individuals under 65 years of age had also been met
and exceeded, with an overall NI uptake rate of 61.3% (range 59.4% to 65.7%).
Final influenza immunisation uptake figures were collected at the end of the 2003/04 campaign and a
detailed report, including clinical risk profile of vaccinated individuals, has been published in the
Monthly Report for March 2004 (Vol 13 No.2), available at http://www.cdscni.org.uk.
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Enhanced Surveillance of Meningococcal
Disease (ESMD) 2003 Calendar Year
Meningococcal disease is a major worldwide cause of morbidity and mortality caused by
bacteria of the species Neisseria meningitidis, of which there are thirteen serogroups. All
serogroups are capable of causing disease. The most important of these are the serogroups
A, B, C and W135, which differ primarily in the structure of their capsules or outer
envelopes. Many people carry strains of Neisseria meningitidis in their nasopharynx
without ever developing invasive disease. In Western Europe and most industrialised
countries, serogroups B and C are responsible for the majority of infections. Meningococcal
disease can occur at any time of year in susceptible individuals. However, in Europe, it
tends to increase notably during the winter months. Further information can be found on
the Health Protection Agency (http://www.hpa.org.uk/) and CDSC (NI) (http://
www.cdscni.org.uk) websites.
Since January 1999, Northern Ireland has participated in a national enhanced surveillance programme
for meningococcal infection. Cases of invasive meningococcal disease are notified to the surveillance
programme throughout the year by CsCDC and the data is validated monthly.
A significant increase in the UK incidence of serogroup C infection during the 1990s led, in 1999, to the
introduction of a meningococcal C conjugate (Men C) vaccine. Prior to such vaccination, serogroup C
infections accounted for around 30-35% of all invasive meningococcal disease cases in the UK. In
England and Wales, between 1999 and 2001, laboratory-confirmed reports of serogroup C infections
fell by 86%. The number of deaths in those less than 20 years of age also fell from 60 in 1999 to 6 in
20011. A similar outcome has also been observed in Northern Ireland. In 1999, when enhanced
surveillance of meningococcal disease commenced, 39% of all laboratory-confirmed cases were due to
serogroup C infection. In the following two years, this figure fell significantly; to 26% in 2000 and 10%
in 2001. No further decrease was recorded during 2002. However, in 2003, less than 5% of all
laboratory confirmed cases in Northern Ireland were due to serogroup C infection.
The enhanced surveillance programme allows the compilation and analysis of all cases of
meningococcal disease, including those with a clinical diagnosis only. Collation of supplementary
information also enables the identification of fatalities and clusters, monitors the impact of the Men C
vaccination programme and highlights any vaccine failures.
The 2003 Northern Ireland dataset is now complete. A total of 116 notifications of meningococcal
disease were received during the calendar year, giving an incidence rate of 6.9 cases per 100,000
population (Table 7). This compares with an incidence rate of approximately 4.6 per 100,000
population for England and Wales over the same period2,3
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Table 7: Cases and rate per 100,000 persons by Health Board, 2003, Northern Ireland
Board Population4 Confirmed Rate Probable Rate All cases Rate
EHSSB 666,860 20 3.0 9 1.3 29 4.3
NHSSB 428,226 33 7.7 4 0.9 37 8.6
SHSSB 312,190 18 5.8 5 1.6 23 7.4
WHSSB 282,043 12 4.3 15 5.3 27 9.6
Northern Ireland 1,689,319 83 4.9 33 2.0 116 6.9
Of the 116 cases notified in 2003, a total of 83 (71.6%) were laboratory confirmed as Neisseria
meningitidis infection. Of these 83 cases; 71 (85.6%) were identified as serogroup B infection, 4 (4.8%)
as serogroup C infection and the remaining 8 (9.6%) cases were ungrouped or identified as other
serogroups (Table 8).
Table 8: Laboratory confirmed cases by Health Board, 2003, Northern Ireland
Board Serogroup B Serogroup C W135 Others and Ungrouped
EHSSB 19 0 0 1
NHSSB 29 0 0 4
SHSSB 15 3 0 0
WHSSB 8 1 0 3
Northern Ireland 71 4 0 8
The number of laboratory confirmed cases, and the proportion of those identified as serogroup B
infection, was almost identical in 2002 and 2003. However, the total number of notifications in 2003
was considerably lower than that recorded for 2002 (116 cases compared to 133 cases).
PCR continues to be an important tool for the rapid diagnosis of meningococcal disease. During 2003,
PCR was used in the diagnosis of 79% of all confirmed cases and as the sole diagnostic tool in 54% of
all confirmed cases. In contrast, culture was used as the sole diagnostic tool in only 20% of confirmed
cases during 2003.
As in previous years, the majority of cases of invasive meningococcal disease in 2003 were reported in
children, particularly those aged 4 years and under (Table 9)
Table 9: Cases and rate per 100,000 persons by age, 2003, Northern Ireland
Age group Population4  B C Others and Ungrouped Total Confirmed Rate
0-2 66929 36 0 4 40 59.8
3-4 47820 9 2 0 11 23.0
5-14 255295 10 1 1 12 4.7
15-17 80670 3 0 0 3 3.7
18-24 159592 7 0 1 8 5.0
25+ 1079013 6 1 2 9 0.8
Total 1689319 71 4 8 83 4.9
Source: CDSC (NI)
Source: CDSC (NI)
Source: CDSC (NI)
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During 2003, three deaths were attributed to invasive meningococcal disease. All occurred in children
(aged 1, 2 and 3 years), all presented with septicaemia and all had laboratory confirmed serogroup B
infection. By comparison, seven deaths occurred during 2002, of which four were in children aged 2
years and under with laboratory confirmed serogroup B infection.
Men C vaccine failures occurred in two fully vaccinated children, aged 3 years and 11 years, during
2003.  There have been a total of four vaccine failures in Northern Ireland since the vaccination
campaign began, in November 1999.
References
1. Balmer, P. & Miller, E. Meningitis C: a Vaccine Update.  Vaccine Action. Issue 8. Spring 2002.
2. Health Protection Agency http://www.hpa.org.uk/cdr/
3. 2002 mid-year population estimates National Statistics Online http://www.statistics.gov.uk/
4. 2001 mid-year population estimates, Northern Ireland Statistics Research Agency http://www.nisra.gov.uk/
Figure 10: Cases of invasive meningococcal disease,
Northern Ireland, 1999-2003
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Enhanced Surveillance of Tuberculosis
Tuberculosis is the leading cause of death worldwide due to any single infectious agent1
and, in 1993, the World Health Organisation declared tuberculosis a global emergency.
It is caused by organisms of the Mycobacterium tuberculosis complex, which include
M. tuberculosis, M. bovis and M. africanum. All three of these organisms are capable of
causing tuberculosis in humans, however it is M. tuberculosis which is of the greatest
public health importance. Infection can take the form of chronic pulmonary infection,
where the organism infects part of the lung and is transmitted by coughing or sneezing.
Non-pulmonary tuberculosis is less common than the pulmonary form and can involve any
organ or tissue, most commonly bone, lymph nodes, central nervous system, skin and the
genito-urinary tract.
The global incidence rate of tuberculosis is growing at approximately 0.4% per year. During 2001, 2.4
million new cases of tuberculosis were reported worldwide, of which half were smear positive. However,
it has been estimated that these 1.2 million new smear positive cases represent only one third of the
true total2.
Tuberculosis disproportionately affects poorer nations and the greatest burden of disease is to be found
in South-East Asia and sub-Saharan Africa. In addition, HIV infection is now the single most important
factor driving the global tuberculosis pandemic. It is estimated that up to 12 million people worldwide
are co-infected with HIV/AIDS and tuberculosis and, of these, 70% live in sub-Saharan Africa3. In future,
particularly in those countries with widespread M.bovis infection of livestock and where conditions
favour zoonotic transmission of infection, this form of tuberculosis may also become an increasing
threat to public health4.
Since the 1990s, multi-drug resistant strains of tuberculosis have emerged throughout the world. These
are defined as strains with resistance to isoniazid and rifampicin, with or without resistance to other
drugs. Although the numbers of tuberculosis isolates has been increasing in the UK since the late
1980’s, the percentage of those displaying multi-drug resistance has remained at the same low level.
Not surprisingly, the highest proportion of multi-drug resistance has been observed in individuals with a
previous history of tuberculosis5. The high incidence of multi-drug resistance in other countries,
especially Eastern Europe, is giving major cause for concern, particularly with the increasing movements
in population from those countries to Western Europe and the UK.
An enhanced surveillance programme for tuberculosis has been operational in Northern Ireland since
1992.  Data collected include: clinical details, treatment, laboratory results and demographic
information.  This enables the production of a detailed annual report on the local epidemiology of
6
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tuberculosis. A national surveillance system commenced in England and Wales in 1999, and Northern
Ireland joined this scheme in 2000.
The next phase of the national surveillance programme commenced in January 2002, with the
collection of treatment outcome information on all tuberculosis cases notified from 1 January 2001.
Outcome data in Northern Ireland is now collected on a standardised ‘Tuberculosis Treatment Outcome
Surveillance Form’, which has been customised for local use.
Once a case has been notified, patient details are entered onto a secure database at CDSC (NI) and
Outcome Forms are generated automatically. These forms are then forwarded, approximately 9 months
after initial notification, to the appropriate Consultant in Communicable Disease Control (CCDC) for
completion by the patients’ clinician.
Notification and Outcome data are validated regularly (using laboratory reports and anti-microbial
resistance information), updated and analysed. The anonymised information is then used for inclusion
in National, European and WHO reports, as well as for disease surveillance at a local level.  As the data
collection process can only be completed 12 months after the initial notification, an annual
epidemiological report does not normally become available until 18 months after the end of the
reporting period. A report presenting the epidemiological data for tuberculosis cases reported in NI
from 1 January 2001 to 31 December 2001 is available at: http://www.cdscni.org.uk/publications
2002 Calendar Year
During 2002, a total of sixty-seven cases of tuberculosis were notified through the enhanced
surveillance scheme. This is equivalent to a rate of 3.9 per 100,000 population, between one third and
one quarter of the rate recorded for England and Wales. Fifty-four of these cases were reported as
pulmonary disease and thirteen as non-pulmonary disease. This represents an increase of over 20%
when compared to 2001, when thirty-six pulmonary and nineteen non-pulmonary cases were notified.
Thirty-nine of the fifty-four pulmonary cases and nine of the thirteen non-pulmonary cases notified in
2002 were confirmed, by culture, to have Mycobacterium tuberculosis infection. The remaining
nineteen cases, although not culture confirmed, were treated on the basis of clinical judgement or
were diagnosed at post mortem. There were no M. bovis isolates cultured from cases notified in 2002.
A report presenting the epidemiological data for tuberculosis cases reported in NI from 1 January 2002
to 31 December 2002 will be prepared during 2004 and published, in due course, on the CDSC (NI)
website.
2003 Calendar Year
Provisional data indicates that, during 2003, a total of fifty-two cases of tuberculosis were notified
through the enhanced surveillance scheme. Thirty-two of these cases were reported as pulmonary
disease and twenty as non-pulmonary disease. Twenty-two of the thirty-two pulmonary cases and
fourteen of the twenty non-pulmonary cases notified in 2003 have, to date, been culture confirmed as
Mycobacterium tuberculosis infection. In addition, M. bovis infection was culture confirmed in two
further non-pulmonary cases notified during 2003.
25
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Tuberculosis in Northern Ireland has, for many decades, been a disease confined largely to older age
groups born in the UK or Ireland. Historically, this has often been due to re-activation of latent disease,
rather than to newly acquired infection. However, recent trends suggest a decrease in the age at which
individuals are becoming infected. Examination of the data also indicates that this decrease in age
cannot be attributed solely to the importation of disease into Northern Ireland from other EU countries,
or from elsewhere.
Although tuberculosis is not considered a major communicable disease problem in Northern Ireland,
changing disease patterns and epidemiology in demographic groups observed elsewhere, and
particularly in England and Wales, indicate the need for vigilance and the importance of functional and
informative surveillance strategies. The predictive value of surveillance systems may well be tested in
the future, particularly with the expansion of the European Union and increasing migration to the UK
both from within, and from outside, Europe.
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Legionella Infections
Bacteria of the genus Legionella consist of 39 species and greater than 60 serogroups,
around half of which have been implicated in causing human disease. The best-known
species is L. pneumophila, and the most common disease causing serogroups are 1 and 6.
They are responsible for causing two types of infection in susceptible individuals; Pontiac
fever and Legionnaires’ Disease. Pontiac Fever is a milder form of infection, where patients
present with ‘flu-like symptoms in the absence of pneumonia. These symptoms develop
quickly and resolve spontaneously in a few days.
Legionnaires’ Disease is a more severe condition associated with significant morbidity and mortality,
particularly amongst immunocompromised patients and the elderly.  Men are more commonly affected
than women.  The primary manifestation is pneumonia, with a dry non-productive cough and severe
‘flu-like symptoms.  Multi-organ involvement can occur with an overall mortality rate of 15-20%, though
this can be much higher in immunocompromised patients.  It can occur sporadically as an uncommon
cause of community-acquired pneumonia, or as cases associated with environmental sources such as
hospitals, hotels and factories.
The organisms survive well in warm, moist environments, even in the presence of chlorine.  Therefore
they are often found in water storage systems, where they survive and profilerate through parasitism of
amoebae.  Transmission to humans takes place via inhalation of contaminated aerosols, in
environments such as saunas, showers, humidifiers and cooling towers.
Legionnaires’ Disease is treated using antibiotics such as erythromycin or tetracycline in community-
acquired cases.  Identification and treatment of any environmental source is also an important part of
disease eradication, and the Health and Safety Executive produces a code of practice for control of the
organism1.  Clusters of disease related to a common environmental source are not unusual, and
guidelines are produced for the investigation of such clusters2, as well as for isolated cases3.  Outbreaks
of the disease can also be related to hotels, and many cases diagnosed in the UK are acquired abroad
by individuals on holiday.
The European Working Group for Legionella Infections (EWGLI) was established in 1986 with the aim of
improving knowledge and information on the clinical and environmental aspects of Legionnaires’
Disease through developments in diagnosis, management and treatment of the disease.  In 1987, the
group initiated a surveillance scheme (EWGLINET), which detects cases of Legionnaires’ Disease among
those staying in hotels or other types of holiday accommodation within Europe.  Information regarding
cases can then be made available to appropriate authorities, for the purposes of investigation.  When
notified of a case of Legionnaires’ Disease which was possibly acquired abroad (within Europe), EWGLI
7
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informs all countries of case notifications and possible country of origin. In addition, EWGLI also aims to
identify clusters relating to particular establishments, and provides cluster alerts to all member
countries.
In Northern Ireland during 2003, seven cases of Legionella infection were notified to CDSC (NI) through
HPA surveillance questionnaires for Legionnaires’ Disease. This is the highest annual total recorded. One
had no symptoms of pneumonia, and was deemed to be Pontiac Fever. One other case had no history
of travel, and was categorised as a sporadic domestic case.
The remaining five travel-associated cases were notified to EWGLINET, and two were part of separate
clusters. One outbreak was related to holiday accommodation in Turkey, and to date has involved one
other case. The remaining cluster was related to accommodation in Bulgaria, which has involved four
other cases of Legionnaires’ Disease, one case of Pontiac Fever and one asymptomatic case. The
remainder of the local cases were associated with travel to Italy, Bulgaria and Portugal. Four (57%) of
the cases were female, and all five involved travel in a European country outside the UK (Table 10).
Ages ranged from 23 years to 70 years, with a median age of 48 years.
Since 1980, 36 cases of Legionnaires’ Disease have been recorded by CDSC (NI). The female:male ratio
was 1:4, and twenty-one (58%) cases were known to have travelled within Europe during the incubation
period of the disease.
Travel Domestic
YEAR Abroad UK Acquired in NI Nosocomial Total Cases Total Deaths
1980 1 0 0 0 1 0
1981 0 0 0 0 0 0
1982 0 0 0 0 0 0
1983 0 0 1 0 1 1
1984 1 0 0 0 2 0
1985 1 0 0 0 1 0
1986 0 0 1 0 1 0
1987 1 0 0 0 1 0
1988 0 0 2 0 2 0
1989 2 0 0 0 2 0
1990 1 0 1 1 1 0
1991 0 0 0 0 0 0
1992 2 0 0 0 2 0
1993 1 0 0 0 1 0
1994 0 1 0 0 1 0
1995 1 0 0 0 1 0
1996 0 0 0 0 0 0
1997 0 0 1 0 1 0
1998 1 0 0 0 1 0
1999 2 0 3 0 5 2
2000 1 0 0 0 1 0
2001 0 0 0 0 0 0
2002 1 0 3 0 4 0
2003 6 0 1 0 7 0
Table10: Legionnaires’ Disease in Northern Ireland, 1980-2003
Source: CDSC (NI)
1. Legionnaires’ Disease: Control of Legionella bacteria in water systems. London. HSE Books
2. Investigation of outbreaks (and single cases) of legionellosis from water systems incorporating cooling towers and
evaporative condensers. HSE, 2002. Available at:http://www.hse.gov.uk/lau/lacs/46-4.htm
3. Lee J V and Joseph C. Guidelines for investigating single cases of legionnaires’ disease. Communicable Disease and
Public Health 2002; 5, 2, 157-162.
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Hepatitis
Hepatitis A
There were 3 laboratory reports of Hepatitis A in 2003, 2 males and 1 female, aged between 12 and 49
years.  There was no history of foreign travel noted for any of the cases.  Laboratory reports of Hepatitis
A have decreased considerably over recent years.  In 2000, 18 reports were received, compared with 5
and 11 in 2001 and 2002 respectively.  Notifications of Hepatitis A have also decreased with 26
received in 2000 compared with 6 in 2001, 1 in 2002 and 4 in 2003.
Figure 11: Notifications and Laboratory Reports of Hepatitis A, 1990-2003,
Northern Ireland
Notifications
Laboratory reports
Source: CDSC (NI)
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Hepatitis B
There were 76 laboratory reports of Hepatitis B received in 2003: 44 males, 29 females and 3 of
unknown gender. The females were aged from 21 years to 46 years, the males from 9 years to 80 years
and the other 3 from 23 years to 45 years. Hepatitis B laboratory reports have generally increased over
recent years with 37 reported in 2001 and 67 in 2002. Twelve (16%) of the 76 laboratory reports
received in 2003 were associated with an acute infection, compared with 8 (12%) of the 67 reports
received in 2002.  None of the Hepatitis B reports received in 2003 were reported to have been
associated with intravenous drug use, although risk factor information is very incomplete. Notifications
of Hepatitis B are considerably lower, with 7 reported in 2001, 8 in 2002 and 21 in 2003.
8
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Figure 12: Notifications and Laboratory Reports of Hepatitis B, 1990-2003,
Northern Ireland
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Hepatitis C
There were 59 laboratory reports of Hepatitis C received in 2003, 50 males and 9 females.  The females
were aged 22 years to 79 years and the males from 17 years to 84 years.  Of the 50 males for whom
laboratory reports were received, it was noted that 6 had experimented with intravenous drugs in the
past and one was HIV positive.  There were no risk factors recorded for any of the female cases.
Laboratory reports of Hepatitis C have fluctuated over recent years; from 1995-2002 laboratory reports
have ranged from 23 to 70 per year.  Hepatitis C is currently not a notifiable disease in Northern Ireland.
Figure 13: Laboratory Reports of Hepatitis C, 1990-2003, Northern Ireland
Cases with history of receipt of unscreened blood/blood products noted
Cases with IVDA noted
Source: CDSC (NI)
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Hepatitis C is the most significant infectious disease affecting those who inject drugs. The Unlinked
Anonymous Prevalence Monitoring Programme of injection drug users was extended to Northern
Ireland in 20021.  Sixteen per cent (12/77) of injecting drug users at the survey sites had antibodies to
Hepatitis C.  Approximately half of injectors with Hepatitis C were aware of their infection. The DHSSPS
will be issuing a Hepatitis C strategy and action plan in 2004 which will address surveillance, clinical and
prevention issues.
References:
1. Shooting Up. Infections among injecting drug users in the UK 2002. An update: December 2003.
Health Protection Agency.
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HIV and AIDS
Northern Ireland participates in the national HIV/AIDS surveillance programme, primarily
based on confidential voluntary reporting of cases by clinicians to the Communicable
Disease Surveillance Centre (Colindale) and the Scottish Centre for Infection and
Environmental Health.
By 31 December 2003 61,100 HIV infected individuals had been reported within the United Kingdom
since surveillance commenced in the 1980s. Table 11 describes the number of HIV infected individuals
and those with AIDS for England, Wales, Scotland and Northern Ireland. In England 64% of HIV infected
individuals were first reported from the London region.
Table 11: HIV infected individuals$ and AIDS cases by country to 31 December 2003
Country HIV AIDS
England 56,286 18,509
Wales 878 294
Scotland 3,657 1,180
Northern Ireland 279 106
United Kingdom 61,100 20,089
By 31 December there were 279 reports of HIV infected individuals$ who were first diagnosed in
Northern Ireland.  This total excludes those initially diagnosed in Great Britain (GB) but who have
returned to Northern Ireland and could be receiving treatment for their infection – these individuals are
included in the GB total.  Figure 14 describes the number of HIV infected individuals$ and AIDS cases by
year of diagnosis since the start of HIV/AIDS surveillance.
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$ Individuals with laboratory reports of infection plus those with AIDS or death reports for whom no
matching laboratory report has been received.
Since HIV surveillance commenced there have been between 9-24 new cases of HIV infection being
reported each year. However, the number of new reports of HIV infection has increased in recent years.
The mean annual number of cases reported between 1988-2002 was 15 – there were 22 cases
reported to date for 2003, and 2002 saw the highest number of cases (24) reported in a single year
since surveillance began.
The effect of enhanced anti-retroviral therapy introduced in 1996 has been to delay progression to AIDS
in those who have had their HIV infection previously diagnosed. There have been 106 AIDS cases
diagnosed in the Province to 31 December 2003.  On average, there have been 6 cases of AIDS
diagnosed annually between 1988-2003. Figure 15 shows that whilst cumulative cases of HIV are
increasing, cumulative cases of AIDS are increasing at a much lower rate.
Figure 14: HIV infected individuals$ & AIDS cases by year of diagnosis,
1985-2003, Northern Ireland
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Figure 15: HIV$ and AIDS cases: cumulative total by year of diagnosis,
1985-2003, Northern Ireland
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Globally, the main exposure category for HIV infection is via heterosexual intercourse. The main
exposure category for HIV infection in Northern Ireland remains sex between men and this accounted
for 153/279 (55%) reports; this proportion is very similar to that noted for the UK. Nevertheless, the
cumulative proportion of cases in who acquired their infection through heterosexual intercourse is
slowly increasing (27%, 28%, 29% by the end of 2000, 2001 and 2002 respectively, rising to 33% by
end of 2003).  Eight (3%) are thought to have acquired HIV infection through injecting drug use, and
this number has shown little change in recent years.
Figure 16: HIV$ infected individuals by exposure category and year of diagnosis,
1986-2003, Northern Ireland
Sex between men
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Source: CDSC (NI)
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$ Individuals with laboratory reports of infection plus those with AIDS or death reports for whom no
matching laboratory report has been received.
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In the UK as a whole, the proportion of those HIV infected individuals thought to have acquired their
infection through injecting drug use is 7%, but in Scotland this proportion is much higher - 33%.
Figure 17: HIV infected individuals$ by exposure category to 31 December
2003, Northern Ireland
N = 279
Sex between men
55% (153) Sex between men& women
33% (92)
IDU 3% (8)
Blood factor/blood or
tissue transfer
7% (20)
Other/undetermined
2% (6)
Source: CDSC (NI)
$ Individuals with laboratory reports of infection plus those with AIDS or death reports for whom no
matching laboratory report has been received.
Table 12: AIDS cases by exposure category to 31 December 2003, Northern Ireland
Exposure category Male Female Total
Sexual intercourse:
between men 59 59
between men & women 15 12 27
Injecting drug use 2 2 4
Blood/blood factor 12 1 13
Other/undetermined 2 1 3
Total 90 16 106
Source: CDSC (NI)
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Syphilis Outbreak in Northern Ireland
2001-2003
The syphilis outbreak identified in October 2001 continued throughout 2002 and 2003,
and is still ongoing. Thirty-six individuals presented to a genito-urinary clinic in 2003
compared with 28 in 2002 and 20 in 2001; one presented in 2000.
By 31 December 2003 85 cases had been reported since 1 July 2000.  All except six were male, and
most (69) were men who have sex with men (MSM); three of whom were bisexual. The mean age of the
cohort was 36 years, range 17-64 years. Cases were resident in all four Boards in Northern Ireland and 6
were non-Northern Ireland residents.
Figure 18: Epidemic Curve: month of presentation at GUM clinic (n=85)
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7
6
5
4
3
2
1
0
Month of presentation at GUM clinic
Ja
n-
01
M
ar
-0
1
N
um
be
r o
f c
as
es
M
ay
-0
1
Ju
l-0
1
Se
p-
01
N
ov
-0
1
Ja
n-
02
M
ar
-0
2
M
ay
-0
2
Ju
l-0
2
Se
p-
02
N
ov
-0
2
Ja
n-
03
M
ar
-0
3
M
ay
-0
3
Ju
l-0
3
Se
p-
03
N
ov
-0
3
One individual presented to the GUM clinic in February 2000 and is not included in the epidemic curve
Most people cited more than one reason for attending the GUM clinic. The majority of cases presented
because they were symptomatic for syphilis or another sexually transmitted disease (STI). Seventeen
cases were identified through contact tracing: four of these were contacts of cases involved in the
Dublin outbreak, and thirteen cases were identified as a result of contact tracing from this outbreak.
One case was a pregnant woman identified through ante-natal screening and her partner was
subsequently identified through contact tracing. Two cases were identified by the Northern Ireland
Blood Transfusion Service.
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Thirty six cases were diagnosed with primary syphilis, 24 with secondary syphilis, 15 with early latent
syphilis and staging was unable to be confirmed in 10 cases.
High risk behaviour
None of the 85 cases admitted to intravenous drug use, and in general, the number of sexual contacts
associated with this cohort is not large. Most (55) had 1 or 2 partners in the three months preceding
infection, although one, a commercial sex worker had between 60 and 70. Only one of the cases was a
commercial sex worker (CSW), and none of the other cases admitted contact with a commercial sex
worker in the three months preceding diagnosis. The CSW was also HIV positive and worked in both
Northern Ireland and Republic of Ireland. Thirty two cases had concomitant sexually transmitted
infections (STIs), and of these, four had two STIs in addition to syphilis infection. Nine cases were HIV
positive (8 of whom were previously aware of their status). This is of particular concern as HIV
transmission may be enhanced by syphilis co-infection.
Figure 19: Concomitant STIs during this episode (n=32)
None of the heterosexuals (6 females, 10 males) considered anal intercourse as the likely route of their
infection. Nine considered that vaginal intercourse was the most likely route of infection, but five were
unable to determine whether their infection was more likely to have been acquired via oral or vaginal
intercourse. Data on the most likely route of infection was available for sixty seven of the MSMs. Thirty
three (48%) considered that oral intercourse was the most likely route of infection and fifteen (22%)
considered that anal intercourse was the most likely route. Nineteen could not conclusively determine
the most likely route of infection (oral-anal). The three bisexual MSMs all considered that the most likely
route of their infection was via oral intercourse.
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The 3 concomitant STIs categorised as ‘other’ were balinitis, bacterial vaginosis (BV),
and scabies together with thrush.
NSU – non-specific urethritis
Source: CDSC (NI)
10
9
8
7
6
5
4
3
2
1
0
HIV + Chlamydia
N
um
be
r o
f C
as
es
NSU Warts Gonorrhea Other
39
COMMUNICABLE DISEASES: Provisional Summary
Individuals diagnosed at the beginning of the outbreak reported sexual contacts in Dublin whereas
individuals presenting more recently appear to have contracted syphilis within Northern Ireland.
Table 13: Likely location at which infection was acquired (n=85)
     Dublin N Ireland Elsewhere in UK Outside British Isles* Unknown
         15 42 7 9 12
*Holland, USA, Spain, South Africa, Canary Islands, Ibiza, Germany
Source: CDSC (NI)
Three cases have had more than one episode of infection since the outbreak began in July 2000. Two
cases have had 2 distinct episodes of infection while the third individual has had three distinct episodes
of infection.
Initiatives to raise awareness of the re-emergence of syphilis commenced in mid-October 2001 and are
ongoing.  As the cohort was not generally associated with a high number of sexual partners, or multiple
anonymous partners, or specific locations, it was difficult to identify a target group within the general
population to implement intervention strategies. However, the outbreak was identified promptly and a
strong network of organisations is continuing to provide information and raise public and professional
awareness. The syphilis outbreak questionnaire was not designed to analyse perceptions of what
constitutes ‘safe sex’, but the data collected suggests that oral sex may be perceived as being less risky
than anal sex, and condoms are not always used even when the subject is aware that they have an STI.
This highlights the need to reiterate the importance of using a condom for oral sex. The challenge is to
raise awareness of sexual health issues, particularly in the heterosexual community, and to educate the
sexually active population about the long-term consequences of infectious syphilis and other STIs, and
of the importance of prevention and early detection if at risk of infection.
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Childhood Vaccination Programme
Vaccination coverage statistics are available for the first three quarters of 2003.
Vaccination uptake among children by their second birthday for diphtheria, tetanus,
pertussis, polio, hib and meningitis C were 95% or greater and show little change from
recent years.
MMR vaccination uptake rates stabilised during 2003 at approximately 87% after having fallen for the
previous four quarters. The lowest MMR vaccine uptake among children by their second birthday since
January 1996 was in Jan-Mar 2003 at 86.9%.  It rose to 87.8% in the second quarter and then fell again
to 87.2 in Jul-Sept.  Despite this, vaccine uptake in Northern Ireland still remains higher than the UK
(Figure 20) and reflects considerable activity at local level by Consultants in Communicable Disease
Control, general practitioners, community medical and nursing staff working with parents and the
media.
Figure 20: MMR Vaccination Uptake Rate at 24 months, 1996-2003,
Northern Ireland and UK
NI
UK
Source: Cover/Korner – CDSC (Colindale)
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The 2003 MMR quarterly uptake rates within Boards varied from 82% – 91% (Figure 21).
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Figure 21: MMR Vaccination Uptake Rates at 24 Months by Board,
1996-2003, Northern Ireland
EHSSB
NHSSB
SHSSB
WHSSB
NI Total
Source: CDSC (NI)
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The salivary testing programme confirmed 55 cases of mumps during 2003. Reports of mumps have
been increasing since September 2003 and this has carried through to 2004. There were no confirmed
cases of measles or rubella but there was one laboratory confirmed case of rubella.
A more detailed report on the childhood vaccination programme, salivary testing programme and
mumps outbreak can be found in Monthly Report Vol 13 No 1.
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1995 1996 1997 1998 1999 2000 2001 2002 2003
Enterics
Adenovirus (faeces only) 205 213 215 138 187 111 143 164 145
Campylobacter 557 653 778 775 862 1001 885 817 740
Clostridium difficile toxin 323 412 423 481 689 718 662 924 1015
Clostridium perfringens 2 11 5 12 6 10 12 20 20
Cryptosporidium 81 98 82 180 181 417 360 126 140
E.coli O157 7 14 30 29 54 54 46 27 53
E. coli O157 (VTEC) 0 0 27 24 49 47 43 27 51
Giardia lamblia 49 45 24 21 37 30 16 12 18
Listeria 5 2 4 6 1 4 5 2 3
Rotavirus 443 379 585 521 357 510 423 391 554
Total Salmonella sp 452 413 432 534 689 425 367 240 213
S.enteritidis 261 171 169 272 462 235 179 98 94
S.enteritidis PT 4 226 113 123 207 397 159 95 32 18
S. paratyphi 0 0 1 2 0 0 0 1 0
S. typhi 1 0 1 1 0 1 3 0 3
S. typhimurium 119 169 185 177 124 93 76 71 43
S. typhimurium DT 104 56 121 134 142 66 37 20 16 10
Shigella 259 154 24 14 12 11 16 9 13
SRSV 31 7 11 35 90 68 131 396 115
Respiratory
Adenovirus (excl faeces) 27 41 87 135 96 72 185 40 25
Chlamydia 48 52 37 43 23 22 21 16 14
Coxiella burnetii 53 62 51 44 53 35 27 27 11
Influenza A 92 131 156 259 419 329 130 47 48
Influenza B 96 4 88 5 158 31 169 8 2
M. pneumoniae 47 23 124 111 20 17 82 64 24
RSV 420 903 1070 651 784 503 407 515 154
Hepatitis A 91 40 37 70 67 18 5 11 3
Hepatitis B 30 31 22 18 24 42 37 67 76
Hepatitis C 63 55 54 65 46 55 65 75 83
M. tuberculosis 65 50 37 32 38 26 42 47 37
M. bovis 2 4 2 0 3 0 2 0 2
S. aureus total (bacteraemia) 205 288 238 271 291 353 428 495 592
MRSA (bacteraemia) 3 26 30 52 69 131 192 186 251
Trends in specific reported pathogens, 1995-2003, Northern Ireland
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Disease 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Acute Encephalitis/
Meningitis:Bacterial* 106 110 89 105 122 98 69 74 48 82 99 68 75 69
Acute Encephalitis/
Meningitis:Viral* 52 62 29 17 22 18 36 17 16 17 31 29 23 9
Anthrax 0 0 0 1 0 0 0 0 0 0 0 0 0 0
Chickenpox * 2744 3578 9955 6699 6138 4785 7004 5253 4907 4584 4531 3927 4931 4459
Cholera 0 0 0 1 1 0 0 0 0 0 0 0 0 0
Diphtheria 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Dysentery 51 66 174 129 136 272 155 29 18 10 24 22 7 14
Food Poisoning 819 636 915 954 1004 1266 1456 1534 1942 2033 2285 1644 1220 1268
Gastro-enteritis
(persons under 2) 1157 1091 1070 1379 888 1072 745 896 1371 1121 1205 1106 882 867
Hepatitis A* 118 225 194 245 229 92 49 33 91 62 26 6 1 4
Hepatitis B* 6 9 14 7 7 8 15 8 1 4 11 7 8 21
Hepatitis Unspecified:Viral* 189 206 96 43 31 22 15 15 16 12 9 10 2 15
Legionnaires’ Disease* 2 1 2 1 1 1 0 2 2 2 1 1 3 4
Leptospirosis* 2 3 1 3 3 0 1 1 2 1 0 0 1 0
Malaria* 4 8 14 8 6 5 14 16 23 13 11 13 2 1
Measles 334 342 303 495 950 263 197 120 112 79 92 96 89 57
Meningococcal Septicaemia* 2 23 27 34 39 42 67 56 87 145 123 90 98 76
Mumps** 187 189 156 115 103 93 67 68 79 93 1006 537 77 180
Paratyphoid Fever 0 0 1 1 2 0 0 1 1 0 0 0 1 0
Plague 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Polio (paralytic) 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Polio (acute) 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Rabies 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Relapsing Fever 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Rubella** 543 357 293 528 408 220 190 127 111 73 62 65 50 34
Scarlet Fever 772 575 525 575 519 502 478 425 486 432 310 283 214 304
Smallpox 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Tetanus 0 0 0 0 1 0 0 1 0 0 0 1 0 0
Tuberculosis (Pulmonary) 94 69 68 69 64 71 51 56 43 44 36 31 58 26
Tuberculosis (Non Pulmonary) 37 27 16 21 29 19 24 19 18 17 22 17 10 12
Typhoid 3 0 0 1 0 0 1 1 2 0 0 1 3 0
Typhus 0 1 0 0 0 0 0 0 0 0 0 0 0 0
Viral Haemorrhagic Fever 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Whooping Cough 285 240 205 134 234 131 148 135 100 108 61 65 69 40
Yellow Fever 0 0 0 0 0 0 0 0 0 0 0 1 0 0
Notifications of Infectious Diseases, 1990-2003, Northern Ireland
* Only notifiable from 16 April 1990          Source:  DHSSPS (NI)
** Only notifiable from October 1988
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